| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,082 | 0,112 | 13:05 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Circio Holding ASA completes directed issue of NOK 3.6 million | 1 | Oslo Børs | ||
| 30.01. | Circio Holding ASA Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement | - | Oslo Børs | ||
| 30.01. | Circio Holding ASA Final results of the oversubscribed rights issue | 2 | Oslo Børs | ||
| 29.01. | Circio Holding ASA Subscription period for the rights issue expires today | 1 | Oslo Børs | ||
| 28.01. | Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders | - | Oslo Børs | ||
| 23.01. | Circio Holding ASA Last day of trading in subscription rights in the rights issue | 2 | Oslo Børs | ||
| CIRCIO Aktie jetzt für 0€ handeln | |||||
| 16.01. | Circio Holding ASA Exercise of subscription rights in the rights issue by primary insiders | 2 | Oslo Børs | ||
| 15.01. | Circio Holding ASA Receipt of subscription rights in the rights issue by primary insiders and their close associates | 1 | Oslo Børs | ||
| 15.01. | Circio Holding ASA Commencement of the subscription period for the rights issue | 2 | Oslo Børs | ||
| 13.01. | Circio Holding ASA Approval and publication of prospectus for the rights issue | 2 | Oslo Børs | ||
| 13.01. | Circio Holding ASA Ex. subscription rights today | 1 | Oslo Børs | ||
| 12.01. | Circio Holding ASA: Circio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue | 1 | Oslo Børs | ||
| 12.01. | Circio Holding ASA Extraordinary general meeting held, all agenda items approved | 1 | Oslo Børs | ||
| 12.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 738 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen | |
| 09.01. | Circio Holding ASA Updated key information relating to the rights issue | 1 | Oslo Børs | ||
| 23.12.25 | Circio Holding ASA Updated information to the notice of extraordinary general meeting 2026 | 1 | Oslo Børs | ||
| 19.12.25 | Circio Holding ASA Notice of extraordinary general meeting on 12 January 2026 | 1 | Oslo Børs | ||
| 08.12.25 | Circio Holding ASA Key information related to the rights issue | 3 | Oslo Børs | ||
| 08.12.25 | Circio Holding ASA: Circio announces 88% underwritten and presubscribed NOK 50 million rights issue with strong support from existing shareholders | 2 | Oslo Børs | ||
| 03.12.25 | Circio Holding ASA: Corr*: Atlas Holdings for CIRCIO | 2 | Oslo Børs |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,148 | +0,79 % | SDAX: Evotec-Aktie schießt zweistellig nach oben | Eine Kaufempfehlung von Berenberg entfacht neuen Optimismus bei Evotec und katapultiert die Biotech-Aktie an die Indexspitze. Die Aktie der Evotec hat am Dienstagmittag ein Kursfeuerwerk gezündet und... ► Artikel lesen | |
| MEDIGENE | 0,042 | -8,26 % | Medigene: Zurückziehung - 18.11.2025 | ||
| PAION | 0,200 | +8,11 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 3,986 | +0,61 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INFLARX | 0,730 | -2,54 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| BAVARIAN NORDIC | 26,050 | +0,19 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,070 | +7,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 9,080 | -1,56 % | Former Emergent BioSolutions CEO Accused Of Insider Trading | WASHINGTON (dpa-AFX) - The former CEO of Emergent BioSolutions, a biopharmaceutical company, is facing accusations of using insider knowledge about COVID-19 vaccine contamination to make over... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 5,850 | +0,21 % | Von der Vision zum Wert: Mesoblast etabliert sich als führendes Unternehmen der globalen Biotechnologie. Teil der ASX "Big Three" zusammen mit CSL und Telix. | ||
| SINOVAC BIOTECH | - | - | Sinovac Biotech Ltd. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal | BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it received... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 4,826 | +0,88 % | SD-Tipp CytomX: Was tun nach +1.438% in 10 Monaten? | Unsere Aktien-Empfehlung CytomX Therapeutics erlebt derzeit einen außergewöhnlich starken Kursverlauf. Innerhalb kurzer Zeit hat sich das Papier von einem lange übersehenen Small-Cap-Titel zu einem... ► Artikel lesen | |
| AGENUS | 2,460 | -1,60 % | Agenus Inc.: Agenus meldet Abschluss einer strategischen Kooperationsvereinbarung mit Zydus Lifesciences im Wert von 141 Millionen US-Dollar zur Weiterentwicklung von BOT+BAL und Stärkung der Produktionskapazitäten in den USA | Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen auf dem Gebiet der Immunonkologie, gab heute den Abschluss seiner bereits angekündigten strategischen Zusammenarbeit mit Zydus Lifesciences... ► Artikel lesen |